Reneural Technologies Limited, formerly known as CardioCrown, is addressing the critical gap in effective and continuous rehabilitation for stroke survivors with its innovative approach to enhance patient outcomes, reduce clinician burnout, and lowes healthcare costs. The company facilitates early discharge from hospitals, improves patient engagement and compliance, while enabling efficient remote care.
With this funding, Reneural plans to grow its VR therapy offerings and expand into mental health support for stroke survivors. The company’s long-term vision is to become a leader in neurorehabilitation, using innovative technologies to improve patient outcomes while reducing the strain on healthcare systems.
The funding round was led by SFC Capital, alongside undisclosed investors, and was completed in conjunction with Innovate UK’s Investor Partnerships SME Round 7.
Reneural has made significant advances in development, with support from Innovate UK’s FastTrack programme in November 2022, securing £50K to build the proof of concept for its Neurorehabilitation platform. The first clinical investigations are set to take place in January, 2025 with support from HTCC SME Accelerators in partnership with University of Hertfordshire. The company is working closely with healthcare professionals and experts to ensure the platform’s success and adoption across clinical pathways, both in hospital settings and at home.
